共表达猪瘟病毒E2抗原与猪IL-18的重组PRRSV活载体疫苗的研制及其免疫原性
本研究以减毒PRRSV株rHuN4-F112反向遗传系统为基础,构建了共表达CSFV E2抗原与猪IL-18的重组病毒rPRRSV-E2-N-IL18,经双酶切、蚀斑试验、间接免疫荧光和Western blotting验证,遗传稳定性至少维持25代。15头PRRSV/CSFV双阴性仔猪随机分为重组疫苗组、亲本病毒组和未接种对照组,接种后35天内疫苗组无PRRSV相关发热,肺、淋巴结和肾脏未见明显炎性病变,并产生针对PRRSV和CSFV E2的特异性抗体,血清IL-18、IL-4和IFN-γ水平显著升高。
要点
- 重组病毒rPRRSV-E2-N-IL18在F25代仍稳定表达外源蛋白。
- 接种后35天内疫苗组无PRRSV相关发热,肺、淋巴结和肾脏未见明显炎性病变。
- 疫苗组产生针对PRRSV和CSFV E2的特异性抗体,血清IL-18、IL-4和IFN-γ水平显著升高。
核心结论
- IL-18可能通过促进Th1/Th2反应间接增强E2免疫原性,诱导较强的体液和细胞免疫。
- 该重组PRRSV平台是同时预防猪PRRSV和CSFV的有前景的多价活载体疫苗策略。
研究设计与样本
- 利用减毒PRRSV株rHuN4-F112反向遗传系统,将CSFV E2基因插入ORF1b与ORF2a之间,将密码子优化的猪IL-18基因整合于ORF7与3'非翻译区之间,构建重组病毒rPRRSV-E2-N-IL18。
- 通过双限制性内切酶消化、蚀斑试验、间接免疫荧光和Western blotting验证重组病毒。
- 15头PRRSV/CSFV双阴性仔猪随机分为重组疫苗组、亲本病毒组和未接种对照组,采用ELISA定量体液和细胞免疫应答,观察接种后35天。
主要发现
- 重组病毒遗传稳定性至少维持25代连续传代,F25代仍可检测到外源蛋白持续表达。
- 接种后35天内疫苗组未观察到PRRSV感染相关发热,肺、淋巴结和肾脏组织病理学检查未见明显炎性病变。
- 接种猪在35天内产生针对PRRSV和CSFV E2的特异性抗体。
- 接种猪血清IL-18、IL-4和IFN-γ水平显著升高,提示Th1/Th2应答增强。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Porcine reproductive and respiratory syndrome virus (PRRSV) and classical swine fever virus (CSFV) are among the most economically devastating viral pathogens in the global swine industry, causing substantial and often incalculable economic losses. In field vaccination programs, the mutual interference between the immune responses elicited by CSFV and PRRSV vaccines markedly restricts the flexibility of immunization schedules, while the limited cross-protective capacity of current PRRSV vaccines remains an inherent and unavoidable challenge in swine disease management. To address these limitations, the present study aimed to develop a recombinant PRRSV-based live vector vaccine co-expressing two exogenous components: the protective E2 antigen of CSFV and porcine interleukin-18 (IL-18), with the objective of enhancing immunogenicity beyond that achievable with conventional monovalent formulations. Using a reverse genetics system derived from the attenuated PRRSV strain rHuN4-F112, the CSFV E2 gene was inserted between open reading frame 1b (ORF1b) and ORF2a, while a codon-optimized porcine IL-18 gene was integrated between ORF7 and the 3' untranslated region. The resulting recombinant virus, designated rPRRSV-E2-N-IL18, was validated through dual restriction endonuclease digestion, plaque assays, indirect immunofluorescence assay, and Western blotting. Genetic stability was maintained for at least 25 serial passages, with persistent exogenous protein expression confirmed in the F25 generation. For immunogenicity assessment, fifteen PRRSV/CSFV double-negative piglets were randomly allocated into three groups: recombinant vaccine, parental virus, and unvaccinated control. Humoral and cellular immune responses were quantified by ELISA. During the 35-day post-vaccination period, no pyrexia associated with PRRSV infection was observed in the vaccine group, and histopathological examination of the lungs, lymph nodes, and kidneys showed no significant inflammatory lesions. Vaccinated pigs produced specific antibodies against both PRRSV and CSFV E2 within 35 days, and exhibited significantly elevated serum IL-18, IL-4, and IFN-γ levels, indicative of a potentiated Th1/Th2 response. These results confirm that IL-18 may indirectly enhance E2 immunogenicity by promoting Th1/Th2 responses, inducing robust humoral and cell-mediated immunity. This recombinant PRRSV platform represents a promising multivalent live vector vaccination strategy for the simultaneous prevention of PRRSV and CSFV in swine.
引用
- Guo Z, Li J, Luo M, et al. Development and immunogenicity of a recombinant PRRSV live vector co-expressing CSFV E2 antigen and porcine IL-18 for multivalent swine vaccination. Vaccine. 2025. PMID: 41167014. doi:10.1016/j.vaccine.2025.127886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。